LifeVantage Announces Completion of International In Vitro Study on the MB System™
LifeVantage (LFVN) has completed an international in vitro cell study on its MB System™, the international formulation of the MindBody GLP-1 System™. The study examined the formula's effects on GLP-1 hormone production in specialized L-cells found in the colon. The research analyzed key genes involved in GLP-1 production and regulation, including GCG, GLP1R, DPP-4, PYY, and PPY.
The study utilized ELISA and fluorescent microscopy to evaluate the two-product system's synergistic potential, which aims to enhance GLP-1 production through L-cell activation and gut microbiome optimization. The US version of the product, launched in October, showed positive results in a 12-week human clinical trial, demonstrating a 140% average increase in GLP-1 production. The international version is scheduled for launch in March.
LifeVantage (LFVN) ha completato uno studio internazionale in vitro sulle cellule riguardante il suo MB System™, la formulazione internazionale del MindBody GLP-1 System™. Lo studio ha esaminato gli effetti della formula sulla produzione dell'ormone GLP-1 nelle cellule L specializzate presenti nel colon. La ricerca ha analizzato geni chiave coinvolti nella produzione e regolazione del GLP-1, tra cui GCG, GLP1R, DPP-4, PYY e PPY.
Lo studio ha utilizzato l'ELISA e la microscopia fluorescente per valutare il potenziale sinergico del sistema a due prodotti, volto a migliorare la produzione di GLP-1 attraverso l'attivazione delle cellule L e l'ottimizzazione del microbioma intestinale. La versione statunitense del prodotto, lanciata in ottobre, ha mostrato risultati positivi in una sperimentazione clinica umana di 12 settimane, dimostrando un aumento medio del 140% nella produzione di GLP-1. La versione internazionale è programmata per il lancio a marzo.
LifeVantage (LFVN) ha completado un estudio internacional in vitro sobre su MB System™, la formulación internacional del MindBody GLP-1 System™. El estudio examinó los efectos de la fórmula sobre la producción de la hormona GLP-1 en las células L especializadas que se encuentran en el colon. La investigación analizó genes clave involucrados en la producción y regulación de GLP-1, incluyendo GCG, GLP1R, DPP-4, PYY y PPY.
El estudio utilizó ELISA y microscopía fluorescente para evaluar el potencial sinérgico del sistema de dos productos, que busca mejorar la producción de GLP-1 a través de la activación de células L y la optimización del microbioma intestinal. La versión estadounidense del producto, lanzada en octubre, mostró resultados positivos en un ensayo clínico humano de 12 semanas, demostrando un aumento promedio del 140% en la producción de GLP-1. La versión internacional está programada para lanzarse en marzo.
LifeVantage (LFVN)는 자사의 MB System™에 대한 국제적인 인 비트로 세포 연구를 완료했습니다. 이는 MindBody GLP-1 System™의 국제적 포뮬레이션입니다. 이 연구는 맹장에 있는 특수 L 세포에서 GLP-1 호르몬 생산에 대한 포뮬러의 영향을 조사했습니다. 해당 연구는 GLP-1 생산 및 조절에 관여하는 주요 유전자들을 분석했습니다. 여기에는 GCG, GLP1R, DPP-4, PYY 및 PPY가 포함됩니다.
이 연구는 ELISA 및 형광 현미경을 활용하여 L 세포 활성화 및 장내 미생물 군 최적화를 통해 GLP-1 생산을 향상시키기 위한 두 가지 제품 시스템의 상승 잠재력을 평가했습니다. 10월에 출시된 미국 제품 버전은 12주 임상 시험에서 긍정적인 결과를 보였으며, GLP-1 생산이 평균 140% 증가했다는 사실을 보여주었습니다. 국제 버전은 3월 출시될 예정입니다.
LifeVantage (LFVN) a complété une étude internationale in vitro sur son MB System™, la formulation internationale du MindBody GLP-1 System™. L'étude a examiné les effets de la formule sur la production de l'hormone GLP-1 dans les cellules L spécialisées trouvées dans le côlon. La recherche a analysé des gènes clés impliqués dans la production et la régulation de la GLP-1, y compris GCG, GLP1R, DPP-4, PYY et PPY.
L'étude a utilisé l'ELISA et la microscopie fluorescente pour évaluer le potentiel synergique du système à deux produits, visant à améliorer la production de GLP-1 grâce à l'activation des cellules L et à l'optimisation du microbiome intestinal. La version américaine du produit, lancée en octobre, a montré des résultats positifs lors d'un essai clinique humain de 12 semaines, démontrant une augmentation moyenne de 140% de la production de GLP-1. La version internationale est prévue pour un lancement en mars.
LifeVantage (LFVN) hat eine internationale in vitro-Zellstudie zu seinem MB System™ abgeschlossen, der internationalen Formulierung des MindBody GLP-1 System™. Die Studie untersuchte die Auswirkungen der Formel auf die Produktion des GLP-1-Hormons in spezialisierten L-Zellen, die im Dickdarm vorkommen. Die Forschung analysierte Schlüsselgene, die an der Produktion und Regulation von GLP-1 beteiligt sind, einschließlich GCG, GLP1R, DPP-4, PYY und PPY.
Die Studie verwendete ELISA und Fluoreszenzmikroskopie, um das synergistische Potenzial des Zwei-Produkt-Systems zu bewerten, dessen Ziel es ist, die GLP-1-Produktion durch Aktivierung der L-Zellen und Optimierung des Mikrobioms zu steigern. Die US-Version des Produkts, die im Oktober auf den Markt kam, zeigte in einer 12-wöchigen klinischen Studie am Menschen positive Ergebnisse und wies einen durchschnittlichen Anstieg der GLP-1-Produktion um 140% auf. Die internationale Version soll im März auf den Markt kommen.
- Previous human clinical trial demonstrated 140% increase in GLP-1 production
- International product launch planned for March, expanding market reach
- Successful US product launch reported in October
- None.
Insights
The successful completion of LifeVantage's international MB System™ study marks a pivotal moment for the company's global expansion in the highly lucrative GLP-1 market. The study's focus on specialized L-cells and key genetic markers (GCG, GLP1R, DPP-4, PYY, PPY) demonstrates a sophisticated scientific approach that could differentiate LFVN in the crowded weight management market.
What's particularly noteworthy is their dual-mechanism strategy: combining L-cell activation through natural ingredients with microbiome optimization via resistant starches. This approach positions LFVN uniquely in the $100+ billion global weight management market, offering a natural alternative to prescription GLP-1 agonists like Wegovy and Ozempic.
The planned March international launch timing is strategic, allowing for:
- Market entry before the summer weight loss season
- Capitalization on the successful U.S. launch momentum
- Expansion into LifeVantage's established international distribution networks
The 140% increase in GLP-1 production demonstrated in their September 2024 clinical trial provides strong validation for their technology. With the international formulation showing similar promise, LFVN is positioned to capture market share in regions where prescription GLP-1 alternatives are either unavailable or cost-prohibitive.
The company's focus on natural ingredients and over-the-counter accessibility could provide a significant competitive advantage, particularly in markets where regulatory barriers for prescription medications are high. The upcoming April Global Convention could serve as a catalyst for international sales momentum, especially if additional positive research data is revealed.
Recent Study Testing International Formulation Shows Significant Increase in GLP-1 Hormone
SALT LAKE CITY, Feb. 04, 2025 (GLOBE NEWSWIRE) -- LifeVantage Corporation® (Nasdaq: LFVN), a leading health and wellness company with products designed to activate optimal health processes at the cellular level, today announced the completion of an international in vitro cell study that investigated the effects of its international formulation for the MindBody GLP-1 System™, known as the MB System™, on activating GLP-1 production.*
The international formula was designed to deliver all the benefits of the US formula while meeting regulatory requirements for all other markets in which LifeVantage operates. The study on the international formula, similar to the one completed on the US formula prior to its launch, was conducted on specialized L-cells found in the colon, where the body naturally produces GLP-1, a critical hormone in weight management and glucose regulation.
Key genes involved in the production and regulation of GLP-1 and associated neuropeptides were thoroughly examined, including:
- GCG: Directs the production of Proglucagon, a precursor protein essential for GLP-1 synthesis.
- GLP1R: Facilitates the creation of receptors that GLP-1 binds to, enabling its biological activity.
- DPP-4: An enzyme that degrades GLP-1, reducing the amount available in the body.
- PYY and PPY: Support the production of neuropeptides that work with GLP-1 along the gut-brain axis to regulate hunger signals.
The study used ELISA (Enzyme-Linked Immunosorbent Assay) to quantify total GLP-1 production, complemented by fluorescent microscopy to visualize the outcomes. The research focused on determining the synergistic potential of the active blends from the two-product system, which was designed to enhance the body’s GLP-1 production through a dual mechanism: direct activation of L-cells with a proprietary blend of five naturally-derived ingredients and optimization of the gut microbiome environment using resistant starches.*
“The completion of this trial and the positive results we’re starting to see with this international formula affirm our success in activating the body’s own production of the GLP-1 hormone,” says Lisa Barnes, VP of R&D and Regulatory at LifeVantage. “We’re excited to bring the MB System™ to our international audience starting in March and provide them with the same life-changing results that have already transformed the health of so many.”
The research-backed MindBody GLP-1 System™ debuted last October in the United States to overwhelming success. Users have reported reduction of food noise and cravings, and improved relationship with food—further validating the findings of a 12-week human clinical trial completed in September 2024, which demonstrated a remarkable
Further details regarding this in vitro study as well as other ongoing research will be revealed at the company’s Global Convention, being held April 24-26, 2025.
About LifeVantage Corporation
LifeVantage Corporation (Nasdaq: LFVN), the Activation company, is a pioneer in nutrigenomics—the study of how nutrition and naturally occurring compounds can unlock your genes and the health coded within. Our products work with your unique biology and help your body make what it needs for health. The line of scientifically validated activators includes the flagship Protandim® family of products, TrueScience® Liquid Collagen, the newest MindBody GLP-1 System™, Activation-supporting nutrients such as Omega, D3+, and the Rise AM & Reset PM System®, as well as AXIO® nootropic energy drink mixes, the full TrueScience® line of skin and hair care products, and Petandim®, a pet supplement formulated to combat oxidative stress in dogs. Our independent Consultants sell our products to Customers and share the business opportunity with entrepreneurs seeking to begin their own business. LifeVantage was founded in 2003 and is headquartered in Lehi, Utah. For more information, visit www.lifevantage.com.*
Public Relations Contact:
Madeline Gossett, CerconeBrownCompany
(704) 620-7673
lifevantage@cerconebrown.com
Investor Relations Contact:
Reed Anderson, ICR
(646) 277-1260
reed.anderson@icrinc.com
| * These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure or prevent any disease. ‡ Results may vary. Typical weight loss using this product in a 12-week weight management program is 1–2 pounds per week. This product should be used in conjunction with a healthy diet and regular exercise. Consult with a healthcare provider before starting any weight loss program. Ω Results based on a randomize 12-week human clinical study. |
FAQ
What were the results of LifeVantage's (LFVN) international MB System study?
When will LifeVantage (LFVN) launch the MB System internationally?
What was the GLP-1 increase shown in LifeVantage's (LFVN) clinical trial?
How does LifeVantage's (LFVN) MB System work to increase GLP-1?
When will LifeVantage (LFVN) reveal more details about the MB System study?
